Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6871 to 6885 of 8905 results

  1. Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]

    In development Reference number: GID-TA11689 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091

    In development Reference number: GID-TA11679 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632

    In development Reference number: GID-TA11631 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

    In development Reference number: GID-TA11523 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

    In development Reference number: GID-TA11455 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774

    Discontinued Reference number: GID-TA11124

    Technology appraisal guidance
    Discontinued

  7. Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]

    In development Reference number: GID-TA10826 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

    In development Reference number: GID-TA10779 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

    Discontinued Reference number: GID-MT517

    Medical technologies guidance
    Discontinued

  10. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]

    Discontinued Reference number: GID-TA11338

    Technology appraisal guidance
    Discontinued

  11. Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]

    In development Reference number: GID-TA11654 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]

    In development Reference number: GID-TA10774 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468]

    In development Reference number: GID-TA11581 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]

    In development Reference number: GID-TA11884 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]

    Discontinued Reference number: GID-TA10018

    Technology appraisal guidance
    Discontinued